Skip to main content

Table 1 (abstract O17). Monthly migraine headache days, average of months 1-6

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

  LFEM HFEM  
Treatment Baseline meana (SD) N LSM change from baseline ± SE LSM change difference ± SE p-valueb Baseline meana (SD) N LSM change from baseline ± SE LSM change difference ± SE p-valueb p-valuec
Placebo 5.8 (1.1) 295 -0.9 ± 0.2    10.9 (2.0) 580 -3.4 ± 0.2    
Galca 120mg 5.8 (1.1) 150 -2.8 ± 0.3 -1.8 ± 0.3 <.001 10.9 (2.0) 286 -5.4 ± 0.3 -2.0 ± 0.3 <.001 .642
Galca 240mg 5.8 (1.2) 145 -2.3 ± 0.3 -1.4 ± 0.3 <.001 10.7 (2.0) 283 -5.5 ± 0.3 -2.1 ± 0.3 <.001 .101
  1. Galca galcanezumab, N number of subjects who have a non-missing baseline value and at least one post-baseline value;
  2. aBased upon subjects with a non-missing baseline value; bp-value vs. placebo; cTreatment-by-subgroup interaction p-value vs. placebo